| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
No direct pharmacological target; DPPC is a structural phospholipid component of cell membranes and liposomal formulations.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as tracers for quantification throughout the drug development process. Due to its potential to alter the pharmacokinetic and metabolic characteristics of medications, deuteration has drawn attention[1].
DPPC-liposomes serve effectively as delivery vehicles for inducing immune responses against GSL antigens in mice; the labeled analog has identical biochemical properties as unlabeled DPPC. |
| ln Vivo |
DPPC-liposomes act as delivery vehicles to induce immune responses against GSL antigens in mice; the d9-labeled version is used for quantification, not efficacy studies.
|
| Enzyme Assay |
Not applicable; stable heavy isotopes are incorporated into drug molecules as tracers for quantitation; detection is via LC-MS/MS.
|
| Cell Assay |
Liposomes prepared with DPPC-d9 are used to study cellular uptake; cells are incubated with labeled liposomes, washed, lysed, and analyzed by LC-MS for lipid content.
|
| Animal Protocol |
DPPC-d9 liposomes are administered to mice (IV, IP, or oral gavage); tissue samples are collected at various time points; extracted lipids are analyzed by LC-MS/MS using DPPC-d9 as internal standard.
|
| ADME/Pharmacokinetics |
Identical to unlabeled DPPC; as a phospholipid, DPPC has low water solubility but can be formulated into liposomes with controlled release properties; the d9 label does not alter PK behavior.
|
| Toxicity/Toxicokinetics |
DPPC is a naturally occurring phospholipid with minimal toxicity; the deuterated analog shares the same safety profile; standard laboratory safety precautions are sufficient.
|
| References |
|
| Additional Infomation |
DPPC-d9 is a research-grade stable isotope-labeled standard; not a drug; has no clinical trial or marketing approval status. For analytical research use only.
|
| Molecular Formula |
C40H71D9NO8P
|
|---|---|
| Molecular Weight |
743.09
|
| Related CAS # |
DPPC;63-89-8
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3457 mL | 6.7287 mL | 13.4573 mL | |
| 5 mM | 0.2691 mL | 1.3457 mL | 2.6915 mL | |
| 10 mM | 0.1346 mL | 0.6729 mL | 1.3457 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
